(Press-News.org) The immunosuppressive drug fingolimod (trade name: Gilenya®) is approved for the treatment of highly-active relapsing-remitting multiple sclerosis (RRMS) in adults. In an early benefit assessment pursuant to "Act on the Reform of the Market for Medicinal Products" (AMNOG), the German Institute for Quality and Efficiency in Health Care (IQWiG) assessed whether fingolimod offers an added benefit compared with the present standard therapy.
According to the findings of the assessment, patients with a rapidly progressive and severe course of disease who take fingolimod experience fewer flu-like symptoms. Under consideration of this advantage on the one hand and the uncertain evidence base on the other, IQWIG has concluded that the data provide a "hint" of a minor added benefit of fingolimod for this group of patients.
Due to a lack of evaluable data, an added benefit is not proven for two further groups of patients.
Separate assessment in three groups of patients
According to the different areas of application, IQWiG performed separate assessments of the drug in three groups of patients. Fingolimod was compared with glatiramer acetate in patients with highly active RRMS who had not responded to a complete and appropriate (usually at least one-year) cycle with beta-interferon (IFN-β).
In patients with highly active RRMS who had not received sufficient IFN-β therapy and in those with rapidly progressive severe RRMS, fingolimod was in each case compared with IFN-β 1a.
Evaluable data only for one group of patients
One relevant study was available for the early benefit assessment, an approval study on fingolimod (TRANSFORMS), which compared treatment with fingolimod versus IFN β 1a in adults with RRMS. However, the study only provided data for one of the three patient groups specified by the Federal Joint Committee (G-BA), namely for those with rapidly progressive severe RRMS.
The manufacturer dossier did not contain evaluable data for a benefit assessment in the other two groups, that is, patients with highly active RRMS who had already received a complete pre-treatment with IFN-β and patients with RRMS who had not received sufficient pre-treatment with IFN-β. An added benefit of fingolimod is therefore not proven for these therapeutic indications.
Fewer flu-like symptoms in some patients
The study results in patients with rapidly progressive severe RRMS did not indicate significant differences between treatment groups for the outcomes "relapse", "progression of disability" and "health-related quality of life". No data were reported for the outcomes "fatigue" and "activities of daily living" for this patient group, even though such data were collected in the study. Likewise, no significant difference was shown between treatment groups regarding the overall rate of side effects (adverse events), serious adverse events, and study discontinuations due to adverse events.
However, for the outcome "frequency of flu-like symptoms" the data provided an indication of less harm: patients treated with fingolimod experienced fewer such symptoms.
Only "hint" of added benefit due to inadequate data
It should be noted that conclusions on the group of patients with rapidly progressive severe RRMS are somewhat uncertain. For example, according to the approval status, this patient group is defined by several disease criteria, but the study participants for whom the manufacturer had presented data did not fulfil all of these criteria and can only be identified indirectly as a patient group in the study pool.
Under consideration of this uncertain evidence base on the one hand and the potential advantage on the other, in summary IQWiG concludes that there is a "hint" of a minor added benefit of fingolimod in patients with rapidly progressive severe RRMS treated with fingolimod compared with those treated with beta-interferon.
G-BA decides on the extent of added benefit
The procedure for inferring the overall conclusion on the extent of added benefit is a proposal from IQWiG. The G-BA, which has opened a formal commenting procedure, decides on the extent of added benefit.
The following extract provides an overview of the results of the benefit assessment performed by IQWiG. The website gesundheitsinformation.de, which is issued by IQWiG, provides easily understandable brief information.
The G-BA website contains both general information on benefit assessments pursuant to §35a Social Code Book V and specific information on the assessment of fingolimod.
INFORMATION: END
Over the past year, some news reports have questioned the long-term viability and popularity of daily deal companies, but the industry shows no evidence of slowing down, according to a new study from Rice University.
In the study, "How Businesses Fare With Daily Deals As They Gain Experience: A Multi-Time Period Study of Daily Deal Performance," Utpal Dholakia examines performance of daily deals using survey data from 641 small- and medium-sized businesses obtained at three time periods: April-May 2011, October 2011, and May 2012. Dholakia is a professor of management ...
Around seven percent of adults suffer from an intolerance to wine. This is the result of a survey presented by Peter Wigand and co-authors in the current edition of Deutsches Ärzteblatt International (Dtsch Arztelb Int 2012; 109 (25): 437-44).
The authors evaluated 948 questionnaires that were returned from the 4000 sent out to randomly selected people between the ages of 20 and 69 years. They found that women (8.9%) were more often affected by an intolerance to wine than men (5.2%). The most commonly reported reactions included flushed and itchy skin and a runny nose. ...
EAST LANSING, Mich. — The stock market should be regulated only during times of extraordinary financial disruptions when speculators can destroy healthy businesses, according to a new study led by a Michigan State University scholar.
The study, in the Journal of Financial Economics, is one of the first to suggest when the U.S. Securities and Exchange Commission should get involved in the market.
The answer: rarely. The SEC should step in only when outside financial disruptions make it impossible for large shareholders to fend off "short sellers" – or speculators betting ...
Does being an intense mother make women unhappy? According to a new study by Kathryn Rizzo and colleagues, from the University of Mary Washington in the US, women who believe in intensive parenting - i.e., that women are better parents than men, that mothering should be child-centred, and that children should be considered sacred and are fulfilling to parents - are more likely to have negative mental health outcomes. The work is published online in Springer's Journal of Child and Family Studies.
Parenting can be quite challenging and requires wide-ranging skills and expertise ...
Using piezoelectric materials, researchers have replicated the muscle motion of the human eye to control camera systems in a way designed to improve the operation of robots. This new muscle-like action could help make robotic tools safer and more effective for MRI-guided surgery and robotic rehabilitation.
Key to the new control system is a piezoelectric cellular actuator that uses a novel biologically inspired technology that will allow a robot eye to move more like a real eye. This will be useful for research studies on human eye movement as well as making video feeds ...
When evaluating job applicants, employers want to be sure that they choose the right person for the job. Many employers, from consulting firms to federal agencies, will ask prospective employees to complete extensive tests and questionnaires to get a better sense of what those employees might be like in an office setting. But new research published in the July 2012 issue of Perspectives on Psychological Science, a journal of the Association for Psychological Science, suggests that a different factor – employee interests – may be a better way to predict who will perform ...
Obesity increases the risk of acute kidney injury (AKI) following cardiac surgery, according to a Vanderbilt study published in the Journal of the American Society of Nephrology.
Considered common after cardiac surgery, AKI represents a fivefold increase in mortality risk within 30 days after the procedure and is associated with longer hospital stays and a range of complications.
The study, led by anesthesiologist Frederic T. (Josh) Billings IV, M.D., M.Sc., followed a sample of 455 cardiac surgery patients at Vanderbilt University Hospital and Brigham and Women's Hospital ...
MANHATTAN, Kan. -- Many patients seem to ignore prescription drug warning labels with instructions that are critical for safe and effective use, according to a study by a Kansas State University researcher working with scientists at Michigan State University.
Consumers, particularly older ones, often overlook prescription drug warning labels in part because the labels fail to attract attention, said Nora Bello, an assistant professor of statistics at Kansas State University. Bello helped investigate the effectiveness of prescription drug warning labels to convey drug ...
Groundbreaking new research in the field of "evolutionary analysis in law" not only provides additional evidence that chimpanzees share the controversial human psychological trait known as the endowment effect – which in humans has implications for law – but also shows the effect can be turned on or off for single objects, depending on their immediate situational usefulness.
In humans, the endowment effect causes people to consider an item they have just come to possess as higher in value than the maximum price they would have paid to acquire it just a moment before. ...
On this July 4th week, U.S. beachgoers are thronging their way to seaside resorts and parks to celebrate with holiday fireworks. But across the horizon and miles out to sea toward the north, the Atlantic Ocean's own spring and summer ritual unfolds. It entails the blooming of countless microscopic plants, or phytoplankton.
In what's known as the North Atlantic Bloom, an immense number of phytoplankton burst into existence, first "greening," then "whitening" the sea as one or more species take the place of others.
What turns on this huge bloom, what starts these ocean ...
